Terumo收购MicroVention公司进入治疗脑血管疾病导管技术市场

Terumo收购MicroVention公司进入治疗脑血管疾病导管技术市场
www.med8th.com | 2006年3月2日

(BW)(TERUMO)(4543.T) Terumo公司宣布收购MicroVention公司；此次收购加速了Terumo公司进入治疗脑血管疾病导管技术高速发展市场的步伐

美国商业新闻2006年2月28日东京消息——

Terumo公司（Terumo Corporation）（东京：4543）（日本东京Shibuya-ku，首席执行官Takashi Wachi）是一家综合医院器械、心血管治疗产品及家用保健品的领先提供商，公司今天宣布已经进入达成收购MicroVention公司（美国加利福尼亚）协议的最后阶段。MicroVention公司是一家私人拥有的医疗器材公司，主要集中于提供治疗脑血管瘤的血管腔环及相关产品。MicroVention公司的多数股东同意通过投票支持此次交易，此项交易有望于2006年3月31日前结束，受一些必需的相关规定所制约。

MicroVention公司成立于1997年，总部位于加利福尼亚州的Aliso Viejo，公司开发和销售创新的拥有专利的水凝胶涂覆环、裸铂金环以及微创血管内治疗脑血管瘤的相关设备。MicroVention公司的HydroCoil?栓子系统和MicroPlex?环系统都是基于最佳的技术，业已证明治疗脑血管瘤非常效率。另外，MicroVention公司最近推出了其V-Trak解脱系统，这是一个用于从大脑中的导管平稳解脱环的设备。MicroVention公司通过其直销人员及分销网络在全球营销和销售其产品。

全球脑血管瘤血管内治疗市场目前就血管腔环来说规模超过了2亿美元，预计在接下来的几年内将呈两位数的增长。过去，脑血管瘤都是通过外科手术进行治疗，这需要施以颅骨切开术。这些手术具有很大的风险，患者手术后也需要很长时间恢复。在使用血管腔环治疗过程中，用股动脉作为血管通路，医用导线和导管通过股动脉被放置和通到脑瘤的位置。脑血管瘤血管内治疗与外科手术治疗相比具有创伤更小的特点，同时也提高了治疗效果。

Terumo公司首席执行官Takashi Wachi说：“在Terumo公司继续拓展其心血管业务的时候，我们认为收购MicroVention公司为Terumo公司通过进入高成长的血管腔环领域来进一步加强我们的干预性治疗业务提供了巨大的战略性机会。Terumo公司希望从这次交易中获取的经验和能力将能够极大地支持Terumo公司在这个关键市场领域里继续取得成功。”

MicroVention公司总裁R. Michael Kleine说：“对MicroVention公司来说，这是成为更大、备受人尊敬的国际公司的一部分的一次巨大的机会，也是通过一个把创新国际产品带向市场的更加广泛的平台，为加速MicroVention公司成长提供了一次巨大幕帷６訫icroVention公司以及与我们业务领域相关的每个人来说，这是具有深远意义的一天，我们非常高兴加入一个可分享我们未来、激情以及竞争精神的公司。”

关于Terumo公司

总部位于日本Shibuya-ku的Terumo公司（ www.terumo.com ）是一次性使用医疗器械，如注射器、血袋以及IV解决方案的领先制造商。Terumo公司在全球血管造影术导线以及灌注产品市场上占有最大的市场份额，也是干预性产品，如导管和支架的领先开发商。

关于MicroVention公司

位于美国加利福尼亚州的MicroVention公司（ www.microvention.com ）是一家私人拥有的医疗器械公司，公司致力于为大脑和未梢血管疾病的血管内治疗开发和销售新的基于导管的技术。公司获得了其MicroPlex环系统和HydroCoil小栓系统用来治疗脑瘤的510(k)正式批准函及CE Mark认证。MicroVention公司通过其在美国、加拿大、法国、德国以及英国的直销人员以及通过在其他国家的分销网络销售其产品。

联系方式：Terumo公司，东京 Satoshi Koga, +81-3-3374-8283 电子邮件：CCD@terumo.co.jp

(BW)(TERUMO)(4543.T) Terumo Announces Acquisition of MicroVention; Acquisition to Facilitate Terumo's Entry into the High Growth Market of Catheter-Based Technologies for the Treatment of Cerebral Vascular Disease

TOKYO--(BUSINESS WIRE)--Feb. 28, 2006--

Terumo Corporation (TOKYO:4543) (Shibuya-ku, Tokyo Japan; CEO Takashi Wachi), a leading provider of general hospital, cardiac and vascular, and home healthcare products, today announced that it has entered into a definitive agreement to acquire MicroVention Inc. (California, USA), a privately held medical device company focused on endovascular coils and related products for the treatment of cerebral aneurysms. A majority of MicroVention's shareholders have agreed to vote in favor of the transaction and it is expected to close by March 31, 2006 subject to the required regulatory clearance.

Founded in 1997 and headquartered in Aliso Viejo, California, MicroVention develops and commercializes novel and proprietary hydrogel-coated and bare platinum coils and related devices for the minimally invasive, endovascular treatment of cerebral vascular aneurysms. MicroVention's HydroCoil(R) Embolic System and MicroPlex(TM) coil system are based on best of breed technology and have proved to be highly effective for the treatment of cerebral aneurysms. In addition, MicroVention recently launched its V-Trak detachment system, a device used to smoothly detach coils from the delivery device in the brain. MicroVention markets and sells its products worldwide through its direct sales force and distributor network.

The worldwide market for the endovascular treatment of cerebral aneurysms, currently estimated at over $200M for endovascular coils, is expected to show a double-digit growth over the next several years. Historically, cerebral aneurysms were treated via a surgical clipping procedure which required a craniotomy. These procedures carry a significant risk and require lengthy patient recovery periods. In an endovascular coiling procedure, vascular access is gained by the femoral artery, through which guidewires and catheters are placed and fed to the site of the cerebral aneurysm. Endovascular treatment of cerebral aneurysms is substantially less invasive than surgical clipping with improved patient outcomes.

"As Terumo continues to expand its cardiac and vascular businesses, we believe that the acquisition of MicroVention provides a great strategic opportunity for Terumo to further strengthen our intervention business by entering the high growth area of endovascular coiling," said Takashi Wachi, Terumo's Chief Executive Officer. "The experience and capabilities Terumo expects to gain from this transaction can significantly contribute to Terumo's sustained success in this key market segment."

"This is a tremendous opportunity for MicroVention to be a part of a much larger and very highly respected international organization and to accelerate MicroVention's growth through a broader platform for bringing novel interventional products to the market," said R. Michael Kleine, President of MicroVention. "This is a great day for MicroVention and everyone who is part of our business family, and we are pleased to be joining a company that shares our vision, passion and competitive spirit."

About Terumo Corporation

Terumo Corporation, headquartered in Shibuya-ku, Japan, (www.terumo.com) is a leading manufacturer of single-use medical devices, such as syringes, blood bags and IV solutions. Terumo has the biggest share of the world markets for angiography guide wires and perfusion products and is a leading developer of interventional products, such as catheters and stents.

About MicroVention, Inc.

MicroVention, Inc., in California, USA, (www.microvention.com) is a privately held medical device company dedicated to the development and commercialization of new catheter-based technologies for the endovascular treatment of cerebral and peripheral vascular diseases. The company has received 510(k) clearance and CE Mark for both its MicroPlex Coil System and the HydroCoil Embolization System to treat cerebral aneurysms. MicroVention sells its products through its direct sales force in the U.S., Canada, France, Germany and the United Kingdom and through distributors in other countries.

CONTACT: Terumo Corporation, Tokyo Satoshi Koga, +81-3-3374-8283 email: CCD@terumo.co.jp